005500 Stock Chart & Stats
$17010.00
-$530.00(-3.02%)
―
--
Day’s Range― - ―
52-Week Range$16,800.00 - $25,900.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
₩205.62B
Enterprise Value$339.34K
Total Cash (Recent Filing)₩8.11B
Total Debt (Recent Filing)₩119.98B
Price to Earnings (P/E)9.9
Beta0.17
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1769.66
Shares Outstanding13,320,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)0.83
Price to Sales (P/S)0.78
P/FCF Ratio24.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
005500 FAQ
What was Samjin Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Samjin Pharmaceutical Co., Ltd. lowest stock price was $16800.00 and its highest was $25900.00 in the past 12 months.
What is Samjin Pharmaceutical Co., Ltd.’s market cap?
Samjin Pharmaceutical Co., Ltd.’s market cap is ₩205.62B.
When is Samjin Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Samjin Pharmaceutical Co., Ltd.’s upcoming earnings report date is Aug 18, 2026 which is in 18 days.
How were Samjin Pharmaceutical Co., Ltd.’s earnings last quarter?
Samjin Pharmaceutical Co., Ltd. released its earnings results on May 18, 2026. The company reported $110.112 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Samjin Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Samjin Pharmaceutical Co., Ltd.’s price is currently Undervalued.
Does Samjin Pharmaceutical Co., Ltd. pay dividends?
Samjin Pharmaceutical Co., Ltd. does not currently pay dividends.
What is Samjin Pharmaceutical Co., Ltd.’s EPS estimate?
Samjin Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Samjin Pharmaceutical Co., Ltd. have?
Samjin Pharmaceutical Co., Ltd. has 13,320,000 shares outstanding.
What happened to Samjin Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Samjin Pharmaceutical Co., Ltd. reported an EPS of $110.112 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.204%.
Which hedge fund is a major shareholder of Samjin Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in KR:005500
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Samjin Pharmaceutical Co., Ltd.
Samjin Pharmaceuticals Co., Ltd. is a South Korean company focused on the discovery and development of pharmaceutical products. Their current portfolio includes SA001, a Phase II clinical asset targeting dry eye and Sjögren's syndrome. In the preclinical stage, they are advancing SJP1803/1804 for macular degeneration, alongside SJP601 and SJP1602, which are designed to combat cancer. Additionally, SPJ1604 and SPJ003 are in clinical phases for treating cancer and diabetes. A broader range of candidates, including SJP1901, SJP1902, SJP1801, and SJP006, are undergoing biological testing for potential applications across cancer, fibrosis, cancer immunotherapy, Alzheimer's disease, Parkinson's disease, and anti-viral conditions. The company was founded in 1968 and is based in Seoul, South Korea.
Bukwang Pharmaceutical Co., Ltd.
―
Daewon Pharmaceutical Co., Ltd
―
YUNGJIN PHARM. CO. LTD
―
Hyundai Pharmaceutical Co., Ltd.
―
Kwang Dong Pharmaceutical Co., Ltd.
―